Johnson & Johnson’s Janssen subsidiary has walked away from a lawsuit against drugmaker Vivus over patents using the anti-seizure medication topiramate for a variety of medical conditions.
Vivus, in turn, has agreed to pay a one-time fee and royalty on its FDA-approved weight-loss drug Qsymia, which combines phentermine and topiramate.
